Edwards Lifesciences (EW) Could Break Through $78.25 Resistance Level Posted: Friday, September 16, 2011 8:08 AM EDT
Edwards Lifesciences Corp (NYSE: EW) closed Thursday's trading session at $76.32. In the past year, the stock has hit a 52-week low of $53.10 and 52-week high of $91.82. Edwards Lifesciences (EW) stock has been showing support around $73.43 and resistance in the $78.25 range. Technical indicators for the stock are Bullish and S&P gives Edwards Lifesciences (EW) a positive 4 STARS (out of 5) buy rating. For a hedged play on Edwards Lifesciences (EW), look at the Nov '11 $75.00 covered call for a net debit in the $70.62 area. That is also the break-even stock price for this trade. This covered call has a duration of 64 days, provides 7.47% downside protection and an assigned return rate of 6.20% for an annualized return rate of 35.37% (for comparison purposes only). A lower-cost hedged play for Edwards Lifesciences (EW) would use a longer term call option in place of the covered call stock purchase. To use this strategy look at going long the Edwards Lifesciences (EW) Jan '13 $45.00 call and selling the Nov '11 $75.00 call for a total debit of $28.30. The trade has a lifespan of 64 days and would provide 3.96% downside protection and an assigned return rate of 6.01% for an annualized return rate of 34% (for comparison purposes only). Edwards Lifesciences (EW) has a current trailing average dividend yield of 0%. [ABR-Seven Summits Research]
Edwards Lifesciences Corp (NYSE: EW) closed Thursday's trading session at $76.32. In the past year, the stock has hit a 52-week low of $53.10 and 52-week high of $91.82. Edwards Lifesciences (EW) stock has been showing support around $73.43 and resistance in the $78.25 range. Technical indicators for the stock are Bullish and S&P gives Edwards Lifesciences (EW) a positive 4 STARS (out of 5) buy rating. For a hedged play on Edwards Lifesciences (EW), look at the Nov '11 $75.00 covered call for a net debit in the $70.62 area. That is also the break-even stock price for this trade. This covered call has a duration of 64 days, provides 7.47% downside protection and an assigned return rate of 6.20% for an annualized return rate of 35.37% (for comparison purposes only). A lower-cost hedged play for Edwards Lifesciences (EW) would use a longer term call option in place of the covered call stock purchase. To use this strategy look at going long the Edwards Lifesciences (EW) Jan '13 $45.00 call and selling the Nov '11 $75.00 call for a total debit of $28.30. The trade has a lifespan of 64 days and would provide 3.96% downside protection and an assigned return rate of 6.01% for an annualized return rate of 34% (for comparison purposes only). Edwards Lifesciences (EW) has a current trailing average dividend yield of 0%. [ABR-Seven Summits Research]
Recent EW News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 12:42:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:13:52 PM
- Two Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits • Business Wire • 03/30/2026 02:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/26/2026 08:07:42 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/26/2026 08:07:14 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/26/2026 08:06:11 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/26/2026 08:05:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 09:10:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2026 08:02:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2026 10:50:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 12:33:53 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2026 09:08:19 PM
- Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose • Business Wire • 02/26/2026 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 10:08:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 10:08:49 PM
- Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences • Business Wire • 02/19/2026 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:16:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:16:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 10:37:29 PM
- Edwards Lifesciences to Present at Citi’s 2026 Unplugged Medtech and Life Sciences Access Day • Business Wire • 02/13/2026 12:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/12/2026 09:54:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/10/2026 09:22:48 PM
- Edwards Lifesciences Reports Fourth Quarter Results • Business Wire • 02/10/2026 09:15:00 PM
- Edwards Lifesciences to Host Earnings Conference Call on February 10, 2026 • Business Wire • 02/03/2026 12:05:00 PM
- Edwards Lifesciences to Present at the TD Cowen 46th Annual Health Care Conference • Business Wire • 02/02/2026 12:05:00 PM



